(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 10.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Vertex Pharmaceuticals's revenue in 2025 is $10,625,800,000.On average, 11 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,042,095,384,111, with the lowest VRTX revenue forecast at $2,898,765,139,997, and the highest VRTX revenue forecast at $3,536,752,751,286. On average, 9 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,326,882,861,811, with the lowest VRTX revenue forecast at $3,159,240,565,075, and the highest VRTX revenue forecast at $3,997,678,674,528.
In 2027, VRTX is forecast to generate $3,681,222,304,978 in revenue, with the lowest revenue forecast at $3,366,628,902,312 and the highest revenue forecast at $4,259,637,468,316.